Tools
Stock profile

Scholar Rock Holding Corp (SRRK)

SRRK · Latest close $48.00 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$48.00
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
1
vs previous quarter

Scholar Rock Holding Corp (SRRK) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 1 fund trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($12.0M bought vs $0 sold). Latest close $48.00 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 26, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $12.0M
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Polen Capital Management — 1 tracked fund hold SRRK. See all holders.

Insider and Congress activity

Insiders bought on the open market (6 purchases, $12.0M) vs 0 sales ($0). Latest buy: Oct 26, 2026. Insider trading

Often held alongside

AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Polen Capital Management0.02%52,132ADDED (+0.3%) Q3 filed Nov 13
Paradigm Biocapital Advisors——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -14.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

60.0423.052024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding308 of 8,857 filers
Long-only filers among them305
Change vs 2026 Q1+36 net · 294 entered · 258 exited
Shares reported, all filers138,685,462
Reported value, all filers$7.3B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2025$0
Net income · FY2025$-377.9M
Total assets · FY2025$404.3M
Shares outstanding121,785,282
Market cap (at latest close)$5.8B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 3, 2026.

Short interest

Shares short · Oct 15, 202622,175,999
Share of shares outstanding18.21%
Days to cover12.72

Shares short at recent settlements — Jul 31, 2026: 17.7M · Aug 14, 2026: 18.2M · Aug 31, 2026: 18.0M · Sep 15, 2026: 19.4M · Sep 30, 2026: 22.7M · Oct 15, 2026: 22.2M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 16K · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.

Insider trading · Form 4

1 insider bought on the open market in the last 90 days (6 purchases, $12.0M), against 0 sales by 0 insiders ($0). Latest buy: Oct 26, 2026.

$1M+ open-market buy

Source: SEC Form 4 filings. Open-market transactions only.

Latest open-market buyTransaction pricePrice change since disclosure
AKKARAJU SRINIVAS · 48,988 shares on Oct 26, 2026 · filed Oct 27, 2026$41.59+4.2% (close Oct 28, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Oct 28, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Oct 26, 2026AKKARAJU SRINIVASBuy48,988$41.59$2.0MSEC filing
Oct 26, 2026AKKARAJU SRINIVASBuy97,982$41.59$4.1MSEC filing
Oct 23, 2026AKKARAJU SRINIVASBuy47,000$41.31$1.9MSEC filing
Oct 23, 2026AKKARAJU SRINIVASBuy94,000$41.31$3.9MSEC filing
Oct 23, 2026AKKARAJU SRINIVASBuy500$41.82$20.9KSEC filing
Oct 23, 2026AKKARAJU SRINIVASBuy1,000$41.82$41.8KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 1, 2026Katie PengDirector1,006$48.6KOct 1, 2026SEC filing
Jul 6, 2026Mohammed QatananiOfficer11,704$640.0KJul 6, 2026SEC filing
Jul 1, 2026Joshua ReedDirector3,053$167.3KJul 1, 2026SEC filing
Jul 1, 2026Jeffrey S. FlierDirector3,053$167.3KJul 1, 2026SEC filing
Jul 1, 2026Kristina BurowDirector3,053$167.3KJul 1, 2026SEC filing
Jul 1, 2026Michael GilmanDirector2,544$139.4KJul 1, 2026SEC filing
Jul 1, 2026Katie PengDirector5,446$298.4KJul 1, 2026SEC filing
Apr 6, 2026Mohammed QatananiOfficer23,408$1.2MApr 6, 2026SEC filing
Feb 23, 2026Mohammed QatananiOfficer8,484$409.9KFeb 23, 2026SEC filing
Jan 22, 2026Mohammed QatananiOfficer14,898$686.1KJan 22, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Oct 7, 2025SCHEDULE 13D/A+16.5% (close Oct 8, 2025 → Nov 17, 2026)

Reference close is the first trading day after the filing (Oct 8, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026Redmile Group, LLCSC 13G/A4,311,0923.6%Jun 30, 2026SEC filing
Aug 13, 2026Invus Public Equities, L.P.SC 13G/A9,575,0138.0%Jun 30, 2026SEC filing
May 15, 2026Redmile Group, LLCSC 13G/A9,066,6217.6%Mar 31, 2026SEC filing
May 15, 2026T. Rowe Price Associates, Inc.SC 13G/A6,206,0445.4%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 10, 2026Wellington Management Group LLPSC 13G5,759,4285.6%Dec 31, 2025SEC filing
Nov 14, 2025T. Rowe Price Associates, Inc.SC 13G/A6,883,4007.2%Sep 30, 2025SEC filing
Oct 7, 2025Samsara BioCapital, L.P.SC 13D/A6,367,6146.6%Oct 3, 2025SEC filing
Aug 14, 2025T. Rowe Price Associates, Inc.SC 13G/A8,761,7849.2%Jun 30, 2025SEC filing
Feb 14, 2025Redmile Group, LLCSC 13G/A9,885,1249.9%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 5 Lobbying Disclosure Act filings named this company as client, 2025–2026; most common issues: Medical/Disease Research/Clinical Labs (3).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Insiders

· Large Insider Buys — Last 90 days: a single buy trade of $1M or more

· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%

· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)

Key figures

· Large Insider Buys — Buy value: $12.0M · Buy txns: 6 · Insiders buying: 1 · Latest buy: Oct 26, 2026

· Insider Net Buying — Buy txns: 6 · Sell txns: 0 · Buy value: $12.0M · Latest buy: Oct 26, 2026

· Distress Risk (Altman Z″) — Z″-Score: -9.91 · Working capital / assets: 0.82 · Retained earnings / assets: -3.22 · EBIT / assets: -0.95 · Equity / liabilities: 1.55

· Excess Accruals (Sloan) — Accruals ratio: -73.4% · Net income: $-377.9M · Operating cash flow: $-300.0M · Investing cash flow: $218.7M

· Auditor Change (8-K 4.01) — Latest event: Jun 3, 2025 · Events in 2 yrs: 2

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2023 Q4, ranked #19 of 50.

Also held by the tracked funds that hold SRRK — ranked by lift, the co-holding pattern described in Methodology: AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) · REPLIGEN CORP (RGEN) · BIO-TECHNE Corp (TECH) · Vaxcyte, Inc. (PCVX).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 10, 20261.01 Entry into a Material Definitive Agreement · 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD DisclosureSEC filing
Sep 15, 20267.01 Regulation FD DisclosureSEC filing
Sep 14, 20267.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

AMGEN INC (AMGN) · Track Record: how the signals scored · Practice timing on SRRK

One email a week: the week’s new filings and research. Subscribe free

← SRPT  ·  SRTA →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.